Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | PDE9A | O76083 | 3/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | PDE6A | P16499 | 1/20 | 0.42 |
| ▸ | PDE6G | P18545 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE6B | P35913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21617539 | 0.81 | PARP1 (0.50) | PARP1KDM4ECA12CA9ADORA2A | |
| SCHEMBL3538780 | 0.78 | PARP1 (0.47) | PARP1KDM4ECA12CA9ADORA2A | |
| SCHEMBL12396542 | 0.75 | PARP1 (0.55) | PARP1KDM4EADORA2AADORA3ADORA1 | |
| SCHEMBL30322789 | 0.75 | PARP1 (0.55) | PARP1KDM4EADORA2AADORA3ADORA1 | |
| SCHEMBL11014041 | 0.75 | PARP1 (0.52) | PARP1KDM4EADORA2AADORA3ADORA1 | |
| SCHEMBL29480586 | 0.75 | PRKD3 (0.49) | PARP1KDM4ECA12CA9DAO | |
| SCHEMBL340944 | 0.75 | PRKD3 (0.49) | PARP1KDM4ECA12CA9DAO | |
| SCHEMBL14933613 | 0.74 | PARP1 (0.77) | PARP1KDM4EDAOATAD2PDE9A | |
| Hydrochloric Acid SCHEMBL30775701 | 0.73 | PRKD3 (0.47) | PARP1KDM4ECA12CA9DAO | |
| Hydrochloric Acid SCHEMBL30594385 | 0.73 | PRKD3 (0.47) | PARP1KDM4ECA12CA9DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563329-A | Novel pyridopyrimidinedione compound and preparation method and application thereof | 上海搜果科技有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-108727367-B | Benzoxazinone compound containing pyridopyrimidinedione, preparation method and application thereof, and herbicide composition | 山东先达农化股份有限公司 | 2021-01-05 | — | — | CN | claimed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | claimed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | claimed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | claimed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | claimed |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | claimed |
| EP-2178562-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010529-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | claimed |
| US-6413724-B1 | SCREENING FOR DRUGS THAT MODULATE ENZYMES OR BIOLOGICAL RECEPTORS | VERSICOR, INC. | 2002-07-02 | — | — | US | claimed |
| US-6025371-A | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones | VERSICOR, INC. (US) | 2000-02-15 | — | — | US | claimed |
| WO-1998018781-A9 | FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS | — | 1998-08-20 | — | — | WO | claimed |
| WO-1998018781-A2 | FUSED 2,4-PYRIMIDINEDIONE COMBINATORIAL LIBRARIES, THEIR PREPARATION AND THE USE OF FUSED 2,4-PYRIMIDINEDIONES DERIVATIVES AS ANTIMICROBIAL AGENTS | VERSICOR, INC. (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | claimed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-3836351-A | METHOD OF CONTROLLING PLANT GROWTH WITH 3-SUBSTITUTED-PYRIDO {8 3,2-d{9 PYRIMIDINE-2,4-(1H,3H)-DIONES | AMCHEM PROD | 1974-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | PARP1 2579/4885KDM4E 2451/4885CA12 2359/4885 |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | TRPV1, OPRL1, OPRK1 | PARP1 2409/4885KDM4E 2779/4885CA12 4719/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | PARP1 2766/4885KDM4E 2825/4885CA12 3093/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | PARP1 2579/4885KDM4E 2451/4885CA12 2359/4885 |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | TRPV2, TRPV1, TRPV3 | PARP1 2405/4885KDM4E 4559/4885CA12 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.